Satraplatin
Item No. 20537

CAS Registry No.: 129580-63-8
Formal Name: (OC-6-43)-bis(acetato-κO)amminedichlorocyclohexanamine-platinum
Synonyms: BMS-182751, BMY 45594, JM 216
MF: C_{10}H_{22}Cl_{2}N_{2}O_{4}Pt
FW: 500.3
Purity: ≥98%
UV/Vis.: λ_{max}: 211 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly

Laboratory Procedures

Satraplatin is supplied as a crystalline solid. A stock solution may be made by dissolving the satraplatin in the solvent of choice. Satraplatin is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of satraplatin in these solvents is approximately 0.5 and 0.16 mg/ml, respectively.

Description

Satraplatin is an orally available antineoplastic platinum(IV) complex.\(^1\) It is more hydrophobic than cisplatin (Item No. 13119) or oxaliplatin (Item No. 13106), which reduces transport-determined acquired resistance.\(^1\) Satraplatin also displays less neurotoxicity in rats than cisplatin or tetraplatin.\(^2\) Satraplatin has a favorable toxicity profile and appears to have clinical activity against a variety of malignancies.\(^3\)

References